Tag: Y-90

ablation

Ablation cheaper than Y-90 or TACE for the treatment of hepatocellular...

Ablation costs are significantly less than those of transarterial chemoembolization (TACE) and Yttrium-90 (Y-90), according to a comparative cost analysis of the three...
NHS

SIRT approved for routine commissioning on the NHS

National Health Service (NHS) England have announced that selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) microspheres will now be routinely commissioned for NHS...

Y-90 radioembolization in hepatocellular carcinoma: “Liver function is key”

Jens Ricke (Department of Radiology, University Hospital LMU Munich, Germany) presented the latest evidence about Y-90 radioembolization in hepatocellular carcinoma (HCC) at the 2019...
randomised

Radiation segmentectomy offers new treatment option for liver cancer

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of...

Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...

Same day Y-90 treatment could become paradigm of the future

While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing...

New data show SIRT does not prolong overall survival in metastatic...

The FOXFIRE, SIRFLOX and FOXFIRE Global randomised studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer with selective internal radiotherapy (SIRT)...

The role of Y-90 radioembolization for cholangiocarcinoma

Y-90 radioembolization is a promising locoregional therapy for a devastating disease with few available treatment options. Ongoing and future clinical trials will help to...

Using Y-90 to achieve bariatric artery radioembolization

Nearly 10 years have passed since Aravind Arepally et al published data from the first gastric artery chemoembolization preclinical trials for the treatment of...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...

BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...